ISO 10993-23 Update: Irritation Testing Strategies and Results Interpretation
WATCH WEBINAR ON-DEMAND
About the webinar
The new ISO 10993-23:2021 Biological evaluation of medical devices — Part 23: Tests for irritation has been published in January, 2021. This update impacts all manufacturers of patient contacting devices, as considering this norm is essential for conducting biocompatibility testing procedures. The recently released document specifies the procedures for the prediction and classification of the irritation potential of medical devices and their constituents. The new standard introduces pre-test considerations for irritation, including in silico and in vitro methods for dermal exposure, and summarizes requirements for in vitro and in vivo testing techniques designed to identify specific ways a medical device, its particles and extracts could cause contact irritation.
The new requirements and the most important updates are discussed in our new live webinar ‘ISO 10993-23 Update: Irritation Testing Strategies and Results Interpretation’ on 01.03.2021.
Some key questions to be discussed during the live event are:
- What are the main changes manufacturers need to be aware of for ISO 10993-23:2021?
- What are the specifics of the testing techniques introduced in the standard?
- What impacts would the revisions have on the testing strategy for the patient contacting devices?
- What key factors do you need to consider in order to correctly interpret the results?
Who should attend:
Managers, directors, engineers, and scientists responsible for research and development, product development, quality assurance, and regulatory compliance.
Speaker
Dr. Helge Gehrke, Head of in vitro Pharmacology and Toxicology, Eurofins Medical Device Testing
“ISO 10993-23 Update: Irritation Testing Strategies and Results Interpretation”
The webinar is presented in ENGLISH.
